Antipsychotic Drugs Market, Global Scenario, Market Size, Outlook, Trend, and Forecast, 2016 – 2025

TABLE OF CONTENTS

Chapter 1        Prefix

1.1    Market Scope

1.2    Report Description

1.3    Research Methodology

1.3.1     Primary Research

1.3.2     Secondary Research

1.3.3     In-house Data Modeling

Chapter 2        Executive Summary

2.1   Global Antipsyschotic Drugs Market Year-on-Year Growth, 2020 – 2028 (%)

Chapter 3        Market Outline

3.1    Market Inclination, Trend, Outlook and Viewpoint

3.2    Market Share Analysis: Company’s Competitive Scenario

3.3    Value Chain Analysis

3.4    Porter’s Five Forces Analysis

3.5    Market Dynamics

3.5.1     Drivers

3.5.1.1     Impact Analysis

3.5.2     Restraints

3.5.2.1     Impact Analysis

3.5.3     Opportunities

Chapter 4        Global Antipsychotic Drugs Market by Mechanism of Action: Market Size and Forecast, 2019 – 2028

4.1    Overview

4.2  D2 Antipsychotic

4.2.1   Current Trend and Analysis

4.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.2.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.3  D2/5HT2A Antagonists

4.3.1   Current Trend and Analysis

4.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.3.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.4  D2/5HT2A Antagonsits

4.4.1   Current Trend and Analysis

4.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.4.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

4.5  D2 Partial Agonists

4.5.1   Current Trend and Analysis

4.5.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

4.5.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

Chapter 5        Global Antipsychotic Drugs Market by Disease Indication: Market Size and Forecast, 2019 – 2028 

5.1  Overview

5.2  Schizophrenia

5.2.1   Current Trend and Analysis

5.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.2.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

5.3  Bipolar Disorder

5.3.1   Current Trend and Analysis

5.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.3.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

5.4  Major Depressive Disorder

5.4.1   Current Trend and Analysis

5.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.4.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

5.5  Other Disease Indications

5.5.1   Current Trend and Analysis

5.5.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

5.5.3   Market Size and Forecast by Region, 2019 - 2028 ($ Billion)

Chapter 6        Global Antipsychotic Drugs Market by Geography: Market Size and Forecast, 2019 - 2028

6.1  Overview

6.1.1   Global Directed Energy Weapons Market Year-on-Year Growth, by region 2020 – 2028 (%)

6.2  North America

6.2.1   Current Trend and Analysis

6.2.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

6.2.3   By Mechanism of Action

6.2.4   By Disease Indication

6.3    Europe

6.3.1   Current Trend and Analysis

6.3.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

6.3.3   By Mechanism of Action

6.3.4   By Disease Indication

6.4    Asia-Pacific

6.4.1   Current Trend and Analysis

6.4.2   Market Size and Forecast, 2019 - 2028 ($ Billion)

6.4.3   By Mechanism of Action

6.4.4   By Disease Indication

6.5    RoW

6.5.1   Current Trend and Analysis

6.5.2   Market Size and Forecast, 2019 – 2028($ Billion)

6.5.3   By Mechanism of Action

6.5.4   By Disease Indication

Chapter 7        Company Profiles   

7.1  Acadia Pharmaceutical, Inc.

7.1.1     Company Overview

7.1.2     Product Portfolio

7.1.3     Business Strategies

7.1.4     Financials

7.1.5     Recent Developments

7.2  Alembic Pharmaceutical, Ltd.

7.2.1     Company Overview

7.2.2     Product Portfolio

7.2.3     Business Strategies

7.2.4     Financials

7.2.5     Recent Developments

7.3  Alexza Pharmaceuticals

7.3.1     Company Overview

7.3.2     Product Portfolio

7.3.3     Business Strategies

7.3.4     Financials

7.3.5     Recent Developments

7.4  Alkermes Plc

7.4.1     Company Overview

7.4.2     Product Portfolio

7.4.3     Business Strategies

7.4.4     Financials

7.4.5     Recent Developments

7.5  Allergan Plc

7.5.1     Company Overview

7.5.2     Product Portfolio

7.5.3     Business Strategies

7.5.4     Financials

7.5.5     Recent Developments

7.6  Apotex, Inc.

7.6.1     Company Overview

7.6.2     Product Portfolio

7.6.3     Business Strategies

7.6.4     Financials

7.6.5     Recent Developments

7.7  Astrazeneca Plc

7.7.1     Company Overview

7.7.2     Product Portfolio

7.7.3     Business Strategies

7.7.4     Financials

7.7.5     Recent Developments

7.8  Aurobindo Pharma

7.8.1     Company Overview

7.8.2     Product Portfolio

7.8.3     Business Strategies

7.8.4     Financials

7.8.5     Recent Developments

7.9  Dr. Reddy’s Laboratories Ltd.

7.9.1     Company Overview

7.9.2     Product Portfolio

7.9.3     Business Strategies

7.9.4     Financials

7.9.5     Recent Developments

7.10       Eli Lilly and Co.

7.10.1   Company Overview

7.10.2   Product Portfolio

7.10.3   Business Strategies

7.10.4   Financials

7.10.5   Recent Developments

7.11       Gedeon Richter Plc

7.11.1   Company Overview

7.11.2   Product Portfolio

7.11.3   Business Strategies

7.11.4   Financials

7.11.5   Recent Developments

7.12       Johnson & Johnson

7.12.1   Company Overview

7.12.2   Product Portfolio

7.12.3   Business Strategies

7.12.4   Financials

7.12.5   Recent Developments

7.13       Lannett Co. Inc.

7.13.1   Company Overview

7.13.2   Product Portfolio

7.13.3   Business Strategies

7.13.4   Financials

7.13.5   Recent Developments

7.14       H. Lundbeck A/S

7.14.1   Company Overview

7.14.2   Product Portfolio

7.14.3   Business Strategies

7.14.4   Financials

7.14.5   Recent Developments

7.15       Lupin Ltd.

7.15.1   Company Overview

7.15.2   Product Portfolio

7.15.3   Business Strategies

7.15.4   Financials

7.15.5   Recent Developments

7.16       Mayne Pharma, Inc.

7.16.1   Company Overview

7.16.2   Product Portfolio

7.16.3   Business Strategies

7.16.4   Financials

7.16.5   Recent Developments

7.17       Mylan NV

7.17.1   Company Overview

7.17.2   Product Portfolio

7.17.3   Business Strategies

7.17.4   Financials

7.17.5   Recent Developments

7.18       Otsuka Holdings Co. Ltd.

7.18.1   Company Overview

7.18.2   Product Portfolio

7.18.3   Business Strategies

7.18.4   Financials

7.18.5   Recent Developments

7.19       Sumitomo Dainippon Pharma Co. Ltd.

7.19.1   Company Overview

7.19.2   Product Portfolio

7.19.3   Business Strategies

7.19.4   Financials

7.19.5   Recent Developments

7.20       Sun Pharmaceutical Industries Ltd.

7.20.1   Company Overview

7.20.2   Product Portfolio

7.20.3   Business Strategies

7.20.4   Financials

7.20.5   Recent Developments

7.21       Teva Pharmaceutical Industries, Ltd.

7.21.1   Company Overview

7.21.2   Product Portfolio

7.21.3   Business Strategies

7.21.4   Financials

7.21.5   Recent Developments

7.22       Torrent Pharmaceutical

7.22.1   Company Overview

7.22.2   Product Portfolio

7.22.3   Business Strategies

7.22.4   Financials

7.22.5   Recent Developments

7.23       Vanda Pharmaceutical, Inc.

7.23.1   Company Overview

7.23.2   Product Portfolio

7.23.3   Business Strategies

7.23.4   Financials

7.23.5   Recent Developments

7.24       Wockhardt

7.24.1   Company Overview

7.24.2   Product Portfolio

7.24.3   Business Strategies

7.24.4   Financials

7.24.5   Recent Developments

7.25       Zydus Pharmaceutical, Inc.

7.25.1   Company Overview

7.25.2   Product Portfolio

7.25.3   Business Strategies

7.25.4   Financials

7.25.5   Recent Developments

Back to top

Payment Options

Single User $3897
Five User $5175
Enterprise $9135
Datapack $1299
Short Report: $1799